Esketamine: Insights into a Novel NMDA Antagonist for TRD (Hough, FDA, 2019)
Introduction: Dr. David Hough’s 2019 FDA report presents a comprehensive overview of esketamine, its development, and its approval as a […]
FDA
Esketamine: A Fast-Acting Treatment for Depression, Explained (Hough, FDA, 2019)
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by
FDA Committees Weigh the Risks and Benefits of Esketamine for TRD (2019)
Introduction: In 2019, the FDA’s Psychopharmacologic Drugs Advisory Committee (PDAC) and Drug Safety and Risk Management Advisory Committee (DSaRM) evaluated
Esketamine: A New Hope for Treatment-Resistant Depression (FDA Advisory Committees, 2019)
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
FDA Drug Approval: A Guide to Regulatory Milestones and Implications (FDA, 2019)
Introduction: The FDA’s drug approval process ensures that new therapies meet high standards of safety and efficacy before they are
How Drugs Get Approved: What the FDA Does and Why It Matters to You (FDA, 2019)
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medications.